Once-daily saquinavir and ritonavir in treatment-experienced HIV-1-infected individuals

A. Soria, N. Gianotti, M. Cernuschi, A. Lazzarin

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

To assess the efficacy of 48 weeks' treatment with saquinavir 1600 mg and ritonavir 100 mg, both given once daily (SQVOD), in drug-experienced HIV-infected patients, a SQVOD-based therapy was offered to 100 treatment-experienced patients via their own physicians. The patients starting this regimen were followed up for 48 weeks. HIV-RNA was assessed by means of NASBA (limit of quantification = 80 copies/mL). Fifteen patients received the SQVOD-based therapy. Six discontinued before week 48 because of failure, toxicity or intolerance due to the high pill burden and gastrointestinal side effects. The median baseline CD4+ cell counts and plasma HIV-RNA levels were 317 cells/μL (range 44-698) and 4.18 log copies/mL (range 2.65-6.18). At week 4, there was a mean decrease of 1.96 log copies/mL (P

Original languageEnglish
Pages (from-to)11-15
Number of pages5
JournalNew Microbiologica
Volume27
Issue number1
Publication statusPublished - Jan 2004

Fingerprint

Saquinavir
Ritonavir
HIV-1
HIV
Self-Sustained Sequence Replication
RNA
Therapeutics
CD4 Lymphocyte Count
Physicians
Pharmaceutical Preparations

Keywords

  • Drug-experienced patients
  • Once-daily antiretroviral therapy
  • Protease inhibitors
  • Saquinavir

ASJC Scopus subject areas

  • Microbiology (medical)
  • Microbiology

Cite this

Once-daily saquinavir and ritonavir in treatment-experienced HIV-1-infected individuals. / Soria, A.; Gianotti, N.; Cernuschi, M.; Lazzarin, A.

In: New Microbiologica, Vol. 27, No. 1, 01.2004, p. 11-15.

Research output: Contribution to journalArticle

Soria, A. ; Gianotti, N. ; Cernuschi, M. ; Lazzarin, A. / Once-daily saquinavir and ritonavir in treatment-experienced HIV-1-infected individuals. In: New Microbiologica. 2004 ; Vol. 27, No. 1. pp. 11-15.
@article{a0a29f5388a54ed098fb21b32a56abfa,
title = "Once-daily saquinavir and ritonavir in treatment-experienced HIV-1-infected individuals",
abstract = "To assess the efficacy of 48 weeks' treatment with saquinavir 1600 mg and ritonavir 100 mg, both given once daily (SQVOD), in drug-experienced HIV-infected patients, a SQVOD-based therapy was offered to 100 treatment-experienced patients via their own physicians. The patients starting this regimen were followed up for 48 weeks. HIV-RNA was assessed by means of NASBA (limit of quantification = 80 copies/mL). Fifteen patients received the SQVOD-based therapy. Six discontinued before week 48 because of failure, toxicity or intolerance due to the high pill burden and gastrointestinal side effects. The median baseline CD4+ cell counts and plasma HIV-RNA levels were 317 cells/μL (range 44-698) and 4.18 log copies/mL (range 2.65-6.18). At week 4, there was a mean decrease of 1.96 log copies/mL (P",
keywords = "Drug-experienced patients, Once-daily antiretroviral therapy, Protease inhibitors, Saquinavir",
author = "A. Soria and N. Gianotti and M. Cernuschi and A. Lazzarin",
year = "2004",
month = "1",
language = "English",
volume = "27",
pages = "11--15",
journal = "New Microbiologica",
issn = "1121-7138",
publisher = "Luigi Ponzio e figlio Editori",
number = "1",

}

TY - JOUR

T1 - Once-daily saquinavir and ritonavir in treatment-experienced HIV-1-infected individuals

AU - Soria, A.

AU - Gianotti, N.

AU - Cernuschi, M.

AU - Lazzarin, A.

PY - 2004/1

Y1 - 2004/1

N2 - To assess the efficacy of 48 weeks' treatment with saquinavir 1600 mg and ritonavir 100 mg, both given once daily (SQVOD), in drug-experienced HIV-infected patients, a SQVOD-based therapy was offered to 100 treatment-experienced patients via their own physicians. The patients starting this regimen were followed up for 48 weeks. HIV-RNA was assessed by means of NASBA (limit of quantification = 80 copies/mL). Fifteen patients received the SQVOD-based therapy. Six discontinued before week 48 because of failure, toxicity or intolerance due to the high pill burden and gastrointestinal side effects. The median baseline CD4+ cell counts and plasma HIV-RNA levels were 317 cells/μL (range 44-698) and 4.18 log copies/mL (range 2.65-6.18). At week 4, there was a mean decrease of 1.96 log copies/mL (P

AB - To assess the efficacy of 48 weeks' treatment with saquinavir 1600 mg and ritonavir 100 mg, both given once daily (SQVOD), in drug-experienced HIV-infected patients, a SQVOD-based therapy was offered to 100 treatment-experienced patients via their own physicians. The patients starting this regimen were followed up for 48 weeks. HIV-RNA was assessed by means of NASBA (limit of quantification = 80 copies/mL). Fifteen patients received the SQVOD-based therapy. Six discontinued before week 48 because of failure, toxicity or intolerance due to the high pill burden and gastrointestinal side effects. The median baseline CD4+ cell counts and plasma HIV-RNA levels were 317 cells/μL (range 44-698) and 4.18 log copies/mL (range 2.65-6.18). At week 4, there was a mean decrease of 1.96 log copies/mL (P

KW - Drug-experienced patients

KW - Once-daily antiretroviral therapy

KW - Protease inhibitors

KW - Saquinavir

UR - http://www.scopus.com/inward/record.url?scp=1842589604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842589604&partnerID=8YFLogxK

M3 - Article

C2 - 14964400

AN - SCOPUS:1842589604

VL - 27

SP - 11

EP - 15

JO - New Microbiologica

JF - New Microbiologica

SN - 1121-7138

IS - 1

ER -